Anticancer IGF1R classes take more knocks

Nat Rev Drug Discov. 2013 Apr;12(4):250. doi: 10.1038/nrd3992.
No abstract available

Publication types

  • News

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacology*
  • Biomarkers / metabolism
  • Drug Design*
  • Drug Industry
  • Humans
  • Molecular Targeted Therapy
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Pyrazoles / adverse effects
  • Pyrazoles / pharmacology
  • Receptor, IGF Type 1 / antagonists & inhibitors*
  • Triazines / adverse effects
  • Triazines / pharmacology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • BMS 754807
  • Biomarkers
  • Pyrazoles
  • Triazines
  • ganitumab
  • Receptor, IGF Type 1